{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:04:14Z","timestamp":1779923054402,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47347-3","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T08:04:51Z","timestamp":1775376291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era"],"prefix":"10.1038","volume":"16","author":[{"given":"Satoshi","family":"Yamasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Misaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"key":"47347_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/leu.2009.19","volume":"23","author":"M Wang","year":"2009","unstructured":"Wang, M. et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23, 1320\u20131328. https:\/\/doi.org\/10.1038\/leu.2009.19 (2009).","journal-title":"Leukemia"},{"issue":"5","key":"47347_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bjh.14699","volume":"181","author":"N Epperla","year":"2018","unstructured":"Epperla, N., Hamadani, M., Fenske, T. S. & Costa, L. J. Incidence and survival trends in mantle cell lymphoma. Br. J. Haematol. 181(5), 703\u2013706. https:\/\/doi.org\/10.1111\/bjh.14699 (2018).","journal-title":"Br. J. Haematol."},{"key":"47347_CR3","doi-asserted-by":"publisher","unstructured":"Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. Haematologica. 100(6), 706\u2013708. https:\/\/doi.org\/10.3324\/haematol.2015.127472 (2015).","DOI":"10.3324\/haematol.2015.127472"},{"key":"47347_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson, A. et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: The phase 2 TARMAC study. Blood 143, 673\u2013684. https:\/\/doi.org\/10.1182\/blood.2023021306 (2024).","journal-title":"Blood"},{"key":"47347_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/JBM.S463946","volume":"15","author":"JM Sancho","year":"2024","unstructured":"Sancho, J. M., Sorigu\u00e9, M. & Rubio-Azpeitia, E. Real-world evidence of relapsed\/refractory mantle cell lymphoma patients and treatments: A systematic review. J. Blood Med. 15, 239\u2013254. https:\/\/doi.org\/10.2147\/JBM.S463946 (2024) (eCollection 2024).","journal-title":"J. Blood Med."},{"key":"47347_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","volume":"38","author":"M Khouja","year":"2024","unstructured":"Khouja, M. et al. Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in mantle cell lymphoma: Results from the EU-MCL network trials. Leukemia 38, 2675\u20132684. https:\/\/doi.org\/10.1038\/s41375-024-02375-8 (2024).","journal-title":"Leukemia"},{"key":"47347_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.clml.2024.02.010","volume":"24","author":"A Ip","year":"2024","unstructured":"Ip, A., Della Pia, A. & Goy, A. H. SOHO state of the art updates and next questions: Treatment evolution of mantle cell lymphoma: Navigating the different entities and biological heterogeneity of mantle cell lymphoma in 2024. Clin. Lymphoma Myeloma Leuk. 24, 491\u2013505. https:\/\/doi.org\/10.1016\/j.clml.2024.02.010 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"47347_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023022353","volume":"145","author":"E Silkenstedt","year":"2025","unstructured":"Silkenstedt, E. & Dreyling, M. Treatment of relapsed\/refractory MCL. Blood 145, 673\u2013682. https:\/\/doi.org\/10.1182\/blood.2023022353 (2025).","journal-title":"Blood"},{"key":"47347_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221080743","volume":"13","author":"JJ Pu","year":"2022","unstructured":"Pu, J. J., Savani, M., Huang, N. & Epner, E. M. Mantle cell lymphoma management trends and novel agents: Where are we going?. Ther. Adv. Hematol. 13, 20406207221080743. https:\/\/doi.org\/10.1177\/20406207221080743 (2022) (eCollection 2022).","journal-title":"Ther. Adv. Hematol."},{"key":"47347_CR10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling, M. et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403, 2293\u20132306. https:\/\/doi.org\/10.1016\/S0140-6736(24)00184-3 (2024).","journal-title":"Lancet"},{"key":"47347_CR11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00277-018-3318-5","volume":"97","author":"S Yamasaki","year":"2018","unstructured":"Yamasaki, S. et al. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. Ann. Hematol. 97, 1445\u20131452. https:\/\/doi.org\/10.1007\/s00277-018-3318-5 (2018).","journal-title":"Ann. Hematol."},{"key":"47347_CR12","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","volume":"8","author":"YW Jeon","year":"2019","unstructured":"Jeon, Y. W. et al. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med. 8, 6860\u20136870. https:\/\/doi.org\/10.1002\/cam4.2565 (2019).","journal-title":"Cancer Med."},{"key":"47347_CR13","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1007\/s12325-022-02258-3","volume":"39","author":"S Rai","year":"2022","unstructured":"Rai, S. et al. Outcomes for recurrent mantle cell lymphoma post-Ibrutinib therapy: A retrospective cohort study from a Japanese administrative database. Adv. Ther. 39, 4792\u20134807. https:\/\/doi.org\/10.1007\/s12325-022-02258-3 (2022).","journal-title":"Adv. Ther."},{"key":"47347_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349509","volume":"42","author":"A Kumar","year":"2022","unstructured":"Kumar, A., Eyre, T. A., Lewis, K. L., Thompson, M. C. & Cheah, C. Y. New directions for mantle cell lymphoma in 2022. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u201315. https:\/\/doi.org\/10.1200\/EDBK_349509 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"47347_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92963-0","volume":"15","author":"Y He","year":"2025","unstructured":"He, Y. et al. POD24-based prognostic signature enables personalized risk stratification in mantle cell lymphoma. Sci. Rep. 15, 8687. https:\/\/doi.org\/10.1038\/s41598-025-92963-0 (2025).","journal-title":"Sci. Rep."},{"key":"47347_CR16","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1182\/bloodadvances.2023011271","volume":"7","author":"R Karmali","year":"2023","unstructured":"Karmali, R. et al. Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Adv. 7, 7361\u20137368. https:\/\/doi.org\/10.1182\/bloodadvances.2023011271 (2023).","journal-title":"Blood Adv."},{"key":"47347_CR17","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/bloodadvances.2024014374","volume":"9","author":"J Pidala","year":"2025","unstructured":"Pidala, J. et al. Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: A multicenter real-world analysis. Blood Adv. 9, 1040\u20131048. https:\/\/doi.org\/10.1182\/bloodadvances.2024014374 (2025).","journal-title":"Blood Adv."},{"issue":"11","key":"47347_CR18","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1182\/bloodadvances.2022009225","volume":"7","author":"N Epperla","year":"2023","unstructured":"Epperla, N. et al. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 7(11), 2287\u20132296. https:\/\/doi.org\/10.1182\/bloodadvances.2022009225 (2023).","journal-title":"Blood Adv."},{"key":"47347_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347 (2020).","journal-title":"N. Engl. J. Med."},{"key":"47347_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1435127","volume":"15","author":"H Wan","year":"2024","unstructured":"Wan, H. et al. Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis. Front. Immunol. 15, 1435127. https:\/\/doi.org\/10.3389\/fimmu.2024.1435127 (2024) (eCollection 2024).","journal-title":"Front. Immunol."},{"key":"47347_CR21","doi-asserted-by":"publisher","unstructured":"Fenske, T. S., Wang, X. V., Till, B. G., Blum, K. A., Lunning, M., Lanzarus, H. M. et al. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients in first complete remission (CR) with undetectable minimal residual disease (uMRD): initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial. Blood. 144 (Suppl. 2), LBA-6. https:\/\/doi.org\/10.1182\/blood-2024-212973 (2024).","DOI":"10.1182\/blood-2024-212973"},{"key":"47347_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","volume":"26","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 26, 200\u2013213. https:\/\/doi.org\/10.1016\/S1470-2045(24)00682-X (2025).","journal-title":"Lancet Oncol."},{"key":"47347_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1532\/IJH97.06239","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta, Y. et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int. J. Hematol. 86, 269\u2013274. https:\/\/doi.org\/10.1532\/IJH97.06239 (2007).","journal-title":"Int. J. Hematol."},{"key":"47347_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta, Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): Scripts for TRUMP data analyses, Part I (variables other than HLA-related data). Int. J. Hematol. 103, 3\u201310. https:\/\/doi.org\/10.1007\/s12185-015-1894-x (2016).","journal-title":"Int. J. Hematol."},{"key":"47347_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01241-9","volume":"15","author":"C Sarkozy","year":"2025","unstructured":"Sarkozy, C. et al. Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Blood Cancer J. 15, 78. https:\/\/doi.org\/10.1038\/s41408-025-01241-9 (2025).","journal-title":"Blood Cancer J."},{"issue":"20","key":"47347_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20), 2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569 (2016).","journal-title":"Blood"},{"key":"47347_CR27","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106, 2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004 (2005).","journal-title":"Blood"},{"key":"47347_CR28","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 15, 825\u2212828 (1995)."},{"key":"47347_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich, A. H. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant. 11, 945\u2013956. https:\/\/doi.org\/10.1016\/j.bbmt.2005.09.004 (2005).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"47347_CR30","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan, S. G. et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125, 1333\u20131338. https:\/\/doi.org\/10.1182\/blood-2014-10-609032 (2015).","journal-title":"Blood"},{"key":"47347_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri, A., Labopin, M., Ciceri, F., Mohty, M. & Nagler, A. Definition of GvHD-free, relapse-free survival for registry-based studies: An ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 51, 610\u2013611. https:\/\/doi.org\/10.1038\/bmt.2015.305 (2016).","journal-title":"Bone Marrow Transplant."},{"issue":"1 Suppl","key":"47347_CR32","first-page":"S1","volume":"18","author":"EA Copelan","year":"2012","unstructured":"Copelan, E. A. et al. Center for international blood and marrow transplant research (CIBMTR) statistical methodology. Biol Blood Marrow Transplant. 18(1 Suppl), S1\u2013S21 (2012).","journal-title":"Biol Blood Marrow Transplant."},{"key":"47347_CR33","first-page":"1141","volume":"16","author":"RJ Gray","year":"1998","unstructured":"Gray, R. J. A class of KK-sample tests for comparing the cumulative incidence of a competing risk. Ann. Statist. 16, 1141\u20131154 (1998).","journal-title":"Ann. Statist."},{"key":"47347_CR34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2014","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2014).","journal-title":"Bone Marrow Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47347-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47347-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:23:17Z","timestamp":1779920597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47347-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47347"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47347-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JK has received honoraria for lectures from Janssen Pharmaceutical K.K. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Transplant Registry Unified Management Program database contains physician-reviewed data. Observational studies based on the Transplant Registry Unified Management Program database are performed with informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Data Management Committee of the Japanese Society for Hematopoietic Cell Transplantation and the Institutional Review Board of St. Mary\u2019s Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"16458"}}